Peri-exposure protection against Nipah virus disease using a single-dose recombinant vesicular stomatitis virus-based vaccine

摘要

Investigators in the United States demonstrate rapid action of a vaccine candidate against the deadly Nipah virus. Researchers of the Laboratory of Virology at the National Institutes of Health and the University of Montana previously discovered a vaccine candidate that was effective in animal models when administered 28 days before exposure to the virus, which is epizootic in certain bats in Southeast Asia. Here they tested their candidate again to determine the time required to afford immunity against the virus, with promising results–the vaccine offered total protection when administered as late as 1 day prior to virus exposure, and was partially effective even up to 1 day post-exposure. These findings offer hope for the production of a viable, quick-acting human vaccine for use in outbreak emergencies of Nipah virus.